Quarterly report · Q2
2796.TEDINET S100SLC9
Period2023-06-01 → 2023-11-30
Filed2024-01-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.7bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥710m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥573m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥701m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥566m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥662m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥394m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥273m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥72m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥282m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥77m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥23.0bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥23.4bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥23.3bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥543m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥703m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥448m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.1bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥792m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥28.29 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.12 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.76 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.08 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.99 | 2023-06-01 → 2023-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥5.93 | 2022-06-01 → 2022-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥162m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥38m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥21m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥831m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥56m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥870m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥872m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2022-11-30 | ¥375m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2022-11-30 | ¥375m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2022-11-30 | ¥26m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥153m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.9bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥3.9bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥129m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥328m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥328m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥38m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥20.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥20.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥744m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥45m |
| —segment total | revenue | 2022-06-01 → 2022-11-30 | ¥25.4bn |
| —segment total | revenue external | 2022-06-01 → 2022-11-30 | ¥25.4bn |
| —segment total | segment profit | 2022-06-01 → 2022-11-30 | ¥699m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥25.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥25.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | ¥726m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 548
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中野区中央一丁目38番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03-3362-7130（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05379 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27960 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ファーマライズホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Pharmarise Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-06-01 | |
| Current period end date | FilingDateInstant | 2023-11-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2024-05-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-06-01 | |
| Comparative period end date | FilingDateInstant | 2022-11-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-05-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所スタンダード市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)株式会社ビックフィールド | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)東京都杉並区南荻窪２丁目18―14 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社スズケン | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)愛知県名古屋市東区東片端町８ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |